Overview of the Treatment of Acne Vulgaris with Topical Retinoids

References

• . Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol. 1995;32(5 pt 3):S15–S25
   Google Scholar
• . Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979;1(6171):1109–1110
   PubMedGoogle Scholar
• . Gollnick H, Cunliffe W, Berson D,; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49( 1 suppl):S1–S37
   PubMed Web of Science ®Google Scholar
• . Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol. 2000;142(6):1084–1091
   PubMed Web of Science ®Google Scholar
• . Gollnick HP, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis related treatment of acne. J Dermatol. 1991;18(9):489–499
   PubMedGoogle Scholar
• . Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 1995;105(2):209–214
   PubMed Web of Science ®Google Scholar
• . Thiboutot D, Knaggs H, Gilliland K, Lin G. Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology. 1998;196(1):38–42
   PubMedGoogle Scholar
• . Thiboutot DM, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol. 1997;136(2):166–171
   PubMedGoogle Scholar
• . Chen W, Zouboulis CC, Fritsch M, Kodelja V, Orfanos CE. Heterogeneity and quantitative differences of type 1 5 alpha-reductase expression in cultured skin epithelial cells. Dermatology. 1998;196(1):51–52
   PubMed Web of Science ®Google Scholar
• . Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol. 2001;116(5):793–800
   PubMed Web of Science ®Google Scholar
• . Pochi PE, Strauss JS, Downing DT. Age-related changes in sebaceous gland activity. J Invest Dermatol. 1979;73(1):108–111
   PubMedGoogle Scholar
• . Schmidt JB, Spona J, Huber J. Androgen receptor in hirsutism and acne. Gynecol Obstet Invest. 1986;22(4):206–211
   PubMedGoogle Scholar
• . Kim J, Ochoa MT, Krutzik SR,. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002;169(3):1535–1541
   PubMed Web of Science ®Google Scholar
• . Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol. 1975;65(4):382–384
   PubMed Web of Science ®Google Scholar
• . Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol. 1988;118(5):651–659
   PubMed Web of Science ®Google Scholar
• . Puhvel SM, Sakamoto M. The chemoattractant properties of comedonal components. J Invest Dermatol. 1978;71(5):324–329
   PubMedGoogle Scholar
• . Charpentier B, Bernardon JM, Eustache J,. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J Med Chem. 1995;38(26):4993–5006
   PubMedGoogle Scholar
• . Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology. 1998;196(1):119–125
   PubMed Web of Science ®Google Scholar
• . Thielitz A, Helmdach M, Röpke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol. 2001;145(1):19–27
   PubMed Web of Science ®Google Scholar
• . Häkkinen L, Westermarck J, Johansson,. Suprabasal expression of epidermal alpha 2 beta 1 and alpha 3 beta 1 integrins in skin treated with topical retinoic acid. Br J Dermatol. 1998;138(1):29–36
   PubMedGoogle Scholar
• . Stewart ME, Benoit AM, Downing DT, Strauss JS. Suppression of sebum secretion with 13-cis-retinoic acid: effect on individual skin surface lipids and implications for their anatomic origin. J Invest Dermatol. 1984;82(1):74–78
   PubMedGoogle Scholar
• . Hughes BR, Cunliffe WJ. A prospective study of the effect of isotretinoin on the follicular reservoir and sustainable sebum excretion rate in patients with acne. Arch Dermatol. 1994;130(3):315–318
   PubMedGoogle Scholar
• . Blaner WS. Cellular metabolism and actions of 13-cis-retinoic acid. J Am Acad Dermatol. 2001;45(5):S129–S135
   Google Scholar
• . Verschoore M, Bouclier M, Czernielewski J, Hensby C. Topical retinoids. Their uses in dermatology. Dermatol Clin. 1993;11(1):107–115
   PubMedGoogle Scholar
• . Hensby C, Cavey D, Bouclier M,. The in vivo and in vitro anti-inflammatory activity of CD271: a new retinoid-like modulator of cell differentiation. Agents Actions. 1990;29(1–2):56–58
   PubMedGoogle Scholar
• . Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol. 2005;174(5):2467–2470
   PubMed Web of Science ®Google Scholar
• . Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16(6):500–506
   PubMed Web of Science ®Google Scholar
• . Thiboutot DM, Weiss J, Bucko A,; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007;57(5):791–799
   PubMed Web of Science ®Google Scholar
• . Gollnick H, Schramm M. Topical therapy in acne. J Eur Acad Dermatol Venereol. 1998;11( suppl 1):S8–S12; discussion S28–S29
   PubMed Web of Science ®Google Scholar
• . Mills OH Jr, Kligman AR. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol. 1978;58(6):555–557
   PubMedGoogle Scholar
• . Ozolins M, Eady EA, Avery AJ,. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet. 2004;364(9452):2188–2195
   PubMed Web of Science ®Google Scholar
• . Stüttgen G. Historical perspectives of tretinoin. J Am Acad Dermatol. 1986;15(4 pt 2):735–740
   PubMedGoogle Scholar
• . Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner. 1976;216(1291):106–109
   PubMedGoogle Scholar
• . Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4(7):473–492
   PubMed Web of Science ®Google Scholar
• . Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol. 1998;38(4):S17–S23
   Google Scholar
• . Skov MJ, Quigley JW, Bucks DA. Topical delivery system for tretinoin: research and clinical implications. J Pharm Sci. 1997;86(10):1138–1143
   PubMed Web of Science ®Google Scholar
• . Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139( suppl 52):34–40
   PubMed Web of Science ®Google Scholar
• . Quigley JW, Bucks DA. Reduced skin irritation with tretinoin containing polyolprepolymer-2, a new topical tretinoin delivery system: a summary of preclinical and clinical investigations. J Am Acad Dermatol. 1998;38(4):S5–S10
   PubMed Web of Science ®Google Scholar
• . Berger R, Barba A, Fleischer A,. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel micro-sphere 0.04% in the treatment of acne vulgaris in adults. Cutis. 2007;80(2):152–157
   PubMedGoogle Scholar
• . Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139( suppl 52):8–11
   PubMed Web of Science ®Google Scholar
• . Medicis Pharmaceutical Corporation. Potency of Tretinoin in the Mixture of CLIN/RA Gel and BPO Gel. Medicis Pharmaceutical Corporation: Scottsdale, AZ; 2006
   Google Scholar
• . Webster G, Cargill DI, Quiring J, Vogelson CT, Slade HB. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne. Cutis. 2009;83(3):146–154
   PubMedGoogle Scholar
• . Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol. 1998;38(4):S24–S30
   Google Scholar
• . Thiboutot DM, Gollnick HP. Treatment considerations for inflammatory acne: clinical evidence for adapalene 0.1% in combination therapies. J Drugs Dermatol. 2006;5(8):785–794
   PubMedGoogle Scholar
• . Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139( suppl 52):48–56
   PubMed Web of Science ®Google Scholar
• . Waugh J, Noble S, Scott LJ. Adapalene: a review of its use in the treatment of acne vulgaris. Drugs. 2004. 64(13):1465–1478
   PubMed Web of Science ®Google Scholar
• . Lucky A, Jorizo JL, Rodriguez D,. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris. Cutis. 2001;68( 4 suppl):34–40
   PubMedGoogle Scholar
• . Thiboutot D, Pariser DM, Egan N; Adapalene Study Group. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006;54(2):242–250
   PubMed Web of Science ®Google Scholar
• . Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M; Adapalene Study Group. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis. 2005;76(2):145–151
   PubMedGoogle Scholar
• . Shalita AR, Chalker DK, Griffith RF,. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63(6):349–354
   PubMedGoogle Scholar
• . Shalita AR, Berson DS, Thiboutot DM,; Tazarotene Cream in Acne Clinical Study Investigator Group. Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther. 2004;26(11):1865–1873
   PubMedGoogle Scholar
• . Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol. 2000;43(2 pt 3):S51–S54
   Google Scholar
• . Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67( 6 suppl):4–9
   PubMedGoogle Scholar
• . Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002;69( 2 suppl):12–19
   PubMedGoogle Scholar
• . Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69( 2 suppl):4–11
   PubMedGoogle Scholar
• . Shalita A, Miller B, Menter A, Abramovits W, Love K, Kakita L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol. 2005;4(2):153–158
   PubMedGoogle Scholar
• . Schlessinger J, Menter A, Gold M,; ZIANA Study Group. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):607–615
   PubMedGoogle Scholar
• . White GM. Acne therapy. Adv Dermatol. 1999;14:29–59
   PubMedGoogle Scholar
• . Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol. 1995;132(2):204–208
   PubMedGoogle Scholar
• . Harper JC. Benzoyl peroxide development, pharmacology, formulation and clinical uses in topical fixed-combinations. J Drugs Dermatol. 2010;9(5):482–487
   PubMedGoogle Scholar
• . Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009;10(15):2555–2562
   PubMed Web of Science ®Google Scholar
• . Gollnick HP, Draelos Z, Glenn MJ,; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161(5):1180–1189
   PubMed Web of Science ®Google Scholar
• . Mills OH Jr, Kligman AM. Assay of comedolytic activity in acne patients. Acta Derm Venereol. 1983;63(1):68–71
   PubMedGoogle Scholar
• . Tanghetti EA, Popp KF. A current review of topical benzoyl peroxide: new perspectives on formulation and utilization. Dermatol Clin. 2009;27(1):17–24
   PubMed Web of Science ®Google Scholar
• . Bowe WP, Shalita AR. Effective over-the-counter acne treatments. Semin Cutan Med Surg. 2008;27(3):170–176
   PubMed Web of Science ®Google Scholar
• . Yentzer BA, Baldwin H, Shalita AR, Webster G, Feldman SK. Optimizing patient adherence: update on combination acne therapy–teens and beyond. J Drugs Dermatol. 2010;9(6):6
   Google Scholar
• . Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics. 2006;118(3):1188–1199
   PubMed Web of Science ®Google Scholar
• . Thiboutot D, Gollnick H, Bettoli V,; Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009. 60( 5 suppl):S1–S50
   PubMed Web of Science ®Google Scholar
• . Webster G. Mechanism-based treatment of acne vulgaris: the value of combination therapy. J Drugs Dermatol. 2005;4(3):281–288
   PubMedGoogle Scholar
• . Weiss JS, Shavin JS. Topical retinoid and antibiotic combination therapy for acne management. J Drugs Dermatol. 2004;3(2):146–154
   PubMedGoogle Scholar
• . Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49( 3 suppl):S200–S210
   PubMed Web of Science ®Google Scholar
• . Campbell JL Jr. A comparative review of the efficacy and tolerability of retinoid-containing combination regimens for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):625–629
   PubMedGoogle Scholar
• . Ghali F, Kang S, Leyden J, Shalita AR, Thiboutot DM. Changing the face of acne therapy. Cutis. 2009;83( 2 suppl):4–15
   PubMed Web of Science ®Google Scholar
• . Webster GF, Graber EM. Antibiotic treatment for acne vulgaris. Semin Cutan Med Surg. 2008;27(3):183–187
   PubMed Web of Science ®Google Scholar
• . Yentzer BA,. Trends in the treatment of acne vulgaris. Poster presented at: 68th Annual Meeting of the American Academy of Dermatology; March 5–10, 2010; Miami, FL
   Google Scholar
• . Pariser DM, Westmoreland P, Morris A, Gold MH, Liu Y, Graeber M. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(9):899–905
   PubMedGoogle Scholar
• . Strauss JS, Rapini RP, Shalita AR,. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10(3):490–496
   PubMed Web of Science ®Google Scholar
• . Bruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin therapy. Cutis. 1984;33(5):484–486, 489
   PubMed Web of Science ®Google Scholar
• . Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22(4):218–220
   PubMedGoogle Scholar
• . Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993;341(8856):1352–1353
   PubMedGoogle Scholar
• . Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, Sarda P, Blayac JP. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother. 1998;32(4):505–506
   PubMedGoogle Scholar
• . Latriano L, Tzimas G, Wong F, Wills RJ. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use. J Am Acad Dermatol. 1997;36(3 pt 2):S37–S46
   Google Scholar
• . Eckhoff C, Nau H. Identification and quantitation of all-trans- and 13-cis-retinoic acid and 13-cis-4-oxoretinoic acid in human plasma. J Lipid Res. 1990;31(8):1445–1454
   PubMedGoogle Scholar
• . Jensen BK, McGann LA, Kachevsky V, Franz TJ. The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol. 1991;24(3):425–428
   PubMed Web of Science ®Google Scholar
• . Cunliffe WJ, Glass D, Goode K, Stables GI, Boorman GC. A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Derm Venereol. 2001;81(1):14–17
   PubMedGoogle Scholar
• . Eichenfield L, Jarratt M, Schlessinger J,; Adapalene Lotion Study Group. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical Studies. J Drugs Dermatol. 2010:9(6);639–646
   PubMedGoogle Scholar
• . Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol. 1998;39(2 pt 3):S67–S73
   Google Scholar
• . Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13(5):575–588
   PubMed Web of Science ®Google Scholar
• . Draelos ZK. Patient compliance: enhancing clinician abilities and strategies. J Am Acad Dermatol. 1995;32(5 pt 3):S42–S48
   Google Scholar
• . Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol. 2003;4(3):197–202
   PubMedGoogle Scholar
• . Laquieze S, Czernielewski J, Rueda MJ. Beneficial effect of a moisturizing cream as adjunctive treatment to oral isotretinoin or topical tretinoin in the management of acne. J Drugs Dermatol. 2006;5(10):985–990
   PubMedGoogle Scholar
• . Bershad S, Kranjac Singer G, Parente JE,. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol. 2002;138(4):481–489
   PubMedGoogle Scholar